TABLE 3

Activities of tedizolid and comparator antimicrobial agents against 3,032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern European, and Latin American countries in 2014

Organism (no. tested) and antimicrobial agentMIC50 (μg/ml)MIC90 (μg/ml)Range (μg/ml)CLSIaEUCASTa
%S%I%R%S%I%R
S. aureus (2,382)
    Tedizolid 800.120.120.03 to 0.25100.00.0100.00.0
    Tedizolid 1000.250.250.03 to 0.5
    Linezolid 8011≤0.12 to 2100.00.0100.00.0
    Linezolid 100220.25 to 4
    Daptomycin0.250.5≤0.06 to 2>99.9>99.9<0.1
    Erythromycin0.25>16≤0.12 to >1669.23.527.269.51.329.2
    Gentamicin≤1>8≤1 to >886.60.413.186.113.9
    Moxifloxacin≤0.122≤0.12 to >482.04.713.382.04.713.3
    Oxacillin0.5>2≤0.25 to >270.629.470.629.4
    Teicoplanin≤2≤2≤2 to 16>99.9<0.10.098.51.5
    Tigecyclineb0.060.06≤0.015 to 0.5100.0100.00.0
    TMP-SMX≤0.5≤0.5≤0.5 to >497.92.197.90.51.6
    Vancomycin110.25 to 2100.00.00.0100.00.0
MSSA (1,681)
    Tedizolid 800.120.120.03 to 0.25100.00.0100.00.0
    Tedizolid 1000.250.250.06 to 0.5
    Linezolid 80110.25 to 2100.00.0100.00.0
    Linezolid 100220.5 to 4
    Daptomycin0.250.5≤0.06 to 299.999.90.1
    Erythromycin0.25>16≤0.12 to >1684.53.312.284.61.114.3
    Gentamicin≤1≤1≤1 to >895.70.34.095.34.7
    Moxifloxacin≤0.12≤0.12≤0.12 to 497.51.11.597.51.11.5
    Teicoplanin≤2≤2≤2 to 4100.00.00.099.90.1
    Tigecycline0.060.06≤0.015 to 0.25100.0100.00.0
    TMP-SMX≤0.5≤0.5≤0.5 to >499.70.399.70.10.2
    Vancomycin110.25 to 2100.00.00.0100.00.0
MRSA (701)
    Tedizolid 800.120.120.03 to 0.25100.00.0100.00.0
    Tedizolid 1000.250.250.03 to 0.5
    Linezolid 8011≤0.12 to 2100.00.0100.00.0
    Linezolid 100120.25 to 4
    Daptomycin0.250.5≤0.06 to 1100.0100.00.0
    Erythromycin>16>16≤0.12 to >1632.74.063.333.31.765.0
    Gentamicin≤1>8≤1 to >864.60.634.864.135.9
    Moxifloxacin2>4≤0.12 to >418.819.761.518.819.761.5
    Teicoplanin≤2≤2≤2 to 1699.90.10.095.14.9
    Tigecycline0.060.12≤0.015 to 0.5100.0100.00.0
    TMP-SMX≤0.5≤0.5≤0.5 to >493.46.693.41.65.0
    Vancomycin110.25 to 2100.00.00.0100.00.0
S. pyogenes (258)
    Tedizolid 800.120.120.06 to 0.25100.0100.00.0
    Tedizolid 1000.120.250.06 to 0.25
    Linezolid 80110.5 to 1100.0100.00.00.0
    Linezolid 100110.5 to 2
    Daptomycin≤0.06≤0.06≤0.06 to 0.25100.0100.00.0
    Erythromycin≤0.120.25≤0.12 to >1690.30.09.790.30.09.7
    Moxifloxacin≤0.120.25≤0.12 to 0.5100.00.00.0
    Penicillin≤0.06≤0.06≤0.06 to 0.12100.0100.00.0
    Teicoplanin≤2≤2≤2 to ≤2100.00.0
    Tigecycline0.030.03≤0.015 to 0.12100.0100.00.00.0
    TMP-SMX≤0.5≤0.5≤0.5 to >498.40.41.2
    Vancomycin0.250.25≤0.12 to 0.5100.0100.00.0
S. agalactiae (145)
    Tedizolid 800.120.120.06 to 0.25100.0100.00.0
    Tedizolid 1000.250.250.06 to 0.5
    Linezolid 80110.5 to 1100.0100.00.00.0
    Linezolid 100110.5 to 2
    Daptomycin0.250.25≤0.06 to 0.5100.0100.00.0
    Erythromycin≤0.12>16≤0.12 to >1670.82.826.470.82.826.4
    Moxifloxacin≤0.120.25≤0.12 to 0.25100.00.00.0
    Penicillin≤0.06≤0.06≤0.06 to 0.12100.0100.00.0
    Teicoplanin≤2≤2≤2 to ≤2100.00.0
    Tigecycline0.030.06≤0.015 to 0.06100.0100.00.00.0
    TMX-SMX≤0.5≤0.5≤0.5 to ≤0.5100.00.00.0
    Vancomycin0.50.5≤0.12 to 1100.0100.00.0
S. anginosus groupc (54)
    Tedizolid 800.060.12≤0.008 to 0.12100.0100.00.0
    Tedizolid 1000.120.25≤0.008 to 0.25
    Linezolid 800.51≤0.12 to 2100.0
    Linezolid 10011≤0.12 to 2
    Daptomycin0.250.5≤0.06 to 1100.0
    Erythromycin≤0.120.5≤0.12 to >1688.91.99.3
    Penicillin≤0.06≤0.06≤0.06 to 0.12100.00.00.0100.00.00.0
    Teicoplanin≤2≤2≤2 to ≤2100.00.0
    Tigecycline0.030.03≤0.015 to 0.06100.0
    Vancomycin0.50.50.25 to 1100.0100.00.0
E. faecalis (193)
    Tedizolid 800.250.250.03 to 0.5100.0
    Tedizolid 1000.250.50.06 to 1
    Linezolid 80120.25 to 499.50.50.0100.00.0
    Linezolid 100220.25 to 4
    Ampicillin120.5 to 8100.00.098.41.60.0
    Daptomycin120.12 to 4100.0
    Erythromycin>16>16≤0.12 to >167.837.554.7
    Teicoplanin≤2≤2≤2 to >1698.40.01.698.41.6
    Tigecycline0.030.06≤0.015 to 0.25100.0100.00.00.0
    TMP-SMX≤0.5≤0.5≤0.5 to >40.025.075.0
    Vancomycin120.5 to >1697.90.51.697.92.1
  • a Criteria as published by CLSI (12) and EUCAST (13). −, breakpoint not available. S, susceptible; R, resistant; I, intermediate.

  • b For tigecycline, U.S. FDA breakpoints were applied when available (Tygacil package insert [2012]; Wyeth Pharmaceuticals Company).

  • c S. constellatus (23 isolates), S. anginosus group (4 isolates), S. anginosus (26 isolates), S. intermedius (1 isolate).